{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-057155","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.319073+00:00","generated_at":"2026-06-07T14:42:03.573658+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Galectin Therapeutics announces 2023 annual meeting results; all director nominees elected","bullets":["All 11 director nominees elected; highest vote total for Kary Eldred at 25,603,577 for.","Ratification of Cherry Bekaert LLP as auditor approved: 44,481,830 for, 252,254 against.","Amendment to 2019 Omnibus Equity Incentive Plan to add 3,000,000 shares approved: 23,901,293 for, 1,923,578 against, 18,910,166 broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-057155","json":"https://secwatch.observer/filing/0001140361-23-057155.json","markdown":"https://secwatch.observer/filing/0001140361-23-057155.md","text":"https://secwatch.observer/filing/0001140361-23-057155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/ef20016443_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:42:03.573658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"850206810aec4a94656c23435ab1798a13b01643","claim":"GALECTIN THERAPEUTICS INC shareholders approved Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023 at the 2023-12-07 meeting.","evidence_excerpt":"Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023 Votes For Votes Against Votes Abstain 44,481,830 252,254 187,704","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"a7a957483b89c206ea6758267578eb898f9c30b8","claim":"GALECTIN THERAPEUTICS INC shareholders approved Election of Directors at the 2023-12-07 meeting.","evidence_excerpt":"Election of Directors Name Votes For Votes Withheld Broker Non-Votes Gilbert F. Amelio, Ph.D. 24,856,340 1,155,282 18,910,166","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"cc3222f7dd721fbc2f93bb76833ab0d2b590b2ea","claim":"GALECTIN THERAPEUTICS INC shareholders approved Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan at the 2023-12-07 meeting.","evidence_excerpt":"Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan. Votes For Votes Against Votes Abstain Broker Non-Votes 23,901,293 1,923,578 186,751 18,910,166","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123057155/0001140361-23-057155-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}